Catalent Zydis® & OSDrC® OptiDoseTM Technologies
Catalent Pharma Solutions is the global leader drug development solutions and advanced delivery technologies for pharmaceutical, biologics and consumer health products.
Catalent Zydis® & OSDrC® OptiDoseTM Technologies
Catalent's Zydis® orally disintegrating tablet (ODT) fast-dissolve formulation, is a unique, freeze-dried oral dosage form that disperses instantly in the mouth, requiring no water. This may enhance the performance and may also contribute towards better patient compliance.
With more than 20 products launched in 50 countries, Zydis is the world's best in class ODT technology. Whether to advance pharmacokinetics through pre-gastric absorption, improve patient compliance, or add marketing advantage to a valued brand, Catalent's customers draw on Zydis fast dissolve technology to potentially enhance investment value and accelerate a product’s potential.
Catalent’s OSDrC® OptiDose™ is an innovative, flexible core tableting technology that enables the formulation and manufacturing of single or multi-cored tablets with differentiated controlled release functionality and a range of unique dose forms, including fixed dose combination tablets.
With shown improvement in mass variability between layers, OptiDose offers tablet design, minimising cross-layer interaction and improving product stability.
In 2014, Catalent will celebrate 80 years of softgel manufacturing and has continually delivered innovation with specialised global manufacturing and innovative technological enhancements such as gelatin-free encapsulation, chewable softgels and enteric coatings, to enable delayed-release of the active ingredient with targeted absorption.
Company name: Catalent Pharma Solutions
Website: www.catalent.com
E-mail:
info@catalent.com
A Discussion: In Vitro Release Testing and Its Application and Use in Generic Topical
December 18th 2024Lucy Zhou, Skin Lab Manager, discusses the importance and applications for utilizing in vitro Release Testing during development of generic topical drug compounds. Lucy discusses how IVRT can play a critical role by saving cost and time during product development and the techniques and applications for using in vitro testing to achieve desired product outcomes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
